Fig. 4From: Adverse Cardiovascular Complications following prescription of programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors: a propensity-score matched Cohort Study with competing risk analysisBoxplots of significant laboratory examination variability stratified by PD-1/PD-L1 inhibitor use and development of the composite outcome in the matched cohortBack to article page